Loading clinical trials...
Loading clinical trials...
Study of Factors Predicting Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma
Results of liver transplantation, the best theoretical treatment for HCC, are limited by tumor recurrence. In order to limit this risk Milan criteria was proposed in 1996. However, these criteria are to restrictive and approximately 40% of patients denied by Milan criteria may be cured by liver transplantation. The purpose of this study was thus to prospectively evaluate factors predicting tumor recurrence after liver transplantation for HCC and then to reassess criteria for liver transplantation.
In this study, the investigators studied the predictive value of imaging techniques such as CT, MRI, PET scan, of serological markers and molecular markers assessed before liver transplantation at listing. The investigators also evaluated the predictive value of tumor growing during the waiting time (imaging and serological). Finally, the investigators compared pre-LT data and explanted liver analysis to evaluate accuracy of liver biopsy and of imaging.
Age
18 - 70 years
Sex
ALL
Healthy Volunteers
No
Clinique Universitaire d'Hépato-gastroentérologie
Grenoble, France
Start Date
January 1, 2009
Primary Completion Date
January 1, 2017
Completion Date
January 1, 2020
Last Updated
November 20, 2020
372
ACTUAL participants
search of factors predicting tumor recurrence
OTHER
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
NCT07485114
NCT06811116
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions